DK0948614T3 - Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme - Google Patents

Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme

Info

Publication number
DK0948614T3
DK0948614T3 DK97954089T DK97954089T DK0948614T3 DK 0948614 T3 DK0948614 T3 DK 0948614T3 DK 97954089 T DK97954089 T DK 97954089T DK 97954089 T DK97954089 T DK 97954089T DK 0948614 T3 DK0948614 T3 DK 0948614T3
Authority
DK
Denmark
Prior art keywords
immunomodulation
treatment
malignancies
autoimmune diseases
expression vectors
Prior art date
Application number
DK97954089T
Other languages
Danish (da)
English (en)
Inventor
Mark Cantwell
Thomas J Kipps
Sanjai Sharma
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0948614T3 publication Critical patent/DK0948614T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK97954089T 1996-12-09 1997-12-08 Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme DK0948614T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3214596P 1996-12-09 1996-12-09
US08/982,272 US7070771B1 (en) 1996-12-09 1997-12-01 Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
PCT/US1997/022740 WO1998026061A2 (en) 1996-12-09 1997-12-08 Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease

Publications (1)

Publication Number Publication Date
DK0948614T3 true DK0948614T3 (da) 2009-05-11

Family

ID=26708033

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97954089T DK0948614T3 (da) 1996-12-09 1997-12-08 Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme

Country Status (16)

Country Link
US (3) US7070771B1 (enExample)
EP (4) EP2145958B1 (enExample)
JP (1) JP4015201B2 (enExample)
CN (1) CN1221662C (enExample)
AT (2) ATE420956T1 (enExample)
AU (1) AU5795798A (enExample)
BR (1) BR9714004A (enExample)
CA (2) CA2274498C (enExample)
DE (1) DE69739220D1 (enExample)
DK (1) DK0948614T3 (enExample)
ES (1) ES2321246T3 (enExample)
IL (3) IL130247A0 (enExample)
NO (2) NO327411B1 (enExample)
NZ (1) NZ336092A (enExample)
PT (1) PT948614E (enExample)
WO (1) WO1998026061A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
IL144952A0 (en) * 1999-04-16 2002-06-30 Hoffmann La Roche Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
GB9917180D0 (en) * 1999-07-23 1999-09-22 Univ Sheffield Cell surface receptor
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
WO2003070271A2 (en) * 2002-02-25 2003-08-28 Isis Innovation Limted Novel complexes for inducing an immune response
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20080044393A1 (en) * 2004-07-16 2008-02-21 White Robert L Retinal dystrophin transgene and methods of use thereof
US20100292309A1 (en) * 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
US20100050276A1 (en) * 2008-08-22 2010-02-25 Brown University Transgenic non-human animal models of apoptosis-mediated conditions
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
KR101989171B1 (ko) * 2012-10-17 2019-06-14 바스큘라 바이오제닉스 리미티드 아데노바이러스를 사용하는 치료 방법
CN106574241A (zh) * 2014-03-27 2017-04-19 密执安大学评议会 癌症免疫疗法组合物和方法
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
CN105567679B (zh) * 2014-10-10 2019-07-05 深圳市北科生物科技有限公司 可分泌型trail蛋白构建物和表达载体
US20180244750A1 (en) 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
US12171803B2 (en) 2017-04-12 2024-12-24 Memgen, Inc. Methods of CD40 and toll like receptor immune activation
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
BR112023023249A2 (pt) * 2021-05-07 2024-01-23 Oyster Point Pharma Inc Fator neurotrófico de codificação de vírion aav e usos do mesmo
US11585330B1 (en) * 2021-09-29 2023-02-21 Halliburton Energy Services, Inc. Flow control for geothermal well

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251037B1 (en) 1986-06-20 1994-06-15 Dainippon Pharmaceutical Co., Ltd. Novel human TNF polypeptide mutants and DNAs encoding said mutants
WO1988009343A1 (fr) 1987-05-29 1988-12-01 Sagami Chemical Research Center Proteine fusionnee contenant une lymphotoxine
ATE148992T1 (de) 1989-08-16 1997-03-15 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
US5519119A (en) 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
DE69333027T2 (de) 1992-03-30 2004-05-06 Immunex Corp., Seattle Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
CZ283533B6 (cs) 1992-04-02 1998-04-15 F. Hoffmann-La Roche Ag TNF - muteiny a způsob jejich výroby
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
JP4242447B2 (ja) 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
EP0679191B1 (en) 1993-01-22 2003-12-10 Immunex Corporation Detection and treatment of mutations in a cd40 ligand gene
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
ATE387458T1 (de) 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
ATE309267T1 (de) 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
JPH09508140A (ja) 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラｔｎｆ結合タンパク質を含有する医薬組成物
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) * 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6016832A (en) * 1997-04-16 2000-01-25 Woodward Governor Company Valve for controlling gas mass flow
CA2304130C (en) 1997-09-17 2008-10-28 Mochida Pharmaceutical Co., Ltd. Novel fas ligand derivative
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
US7070771B1 (en) 2006-07-04
ATE547524T1 (de) 2012-03-15
EP2145958B1 (en) 2012-02-29
NO331434B1 (no) 2011-12-27
CN1221662C (zh) 2005-10-05
ES2321246T3 (es) 2009-06-03
JP2001505782A (ja) 2001-05-08
NO992756D0 (no) 1999-06-07
NO20074906L (no) 1999-08-09
IL130247A (en) 2008-03-20
JP4015201B2 (ja) 2007-11-28
PT948614E (pt) 2009-04-20
EP2145958A1 (en) 2010-01-20
US7906638B2 (en) 2011-03-15
CA2274498A1 (en) 1998-06-18
CN1246892A (zh) 2000-03-08
EP2287309A1 (en) 2011-02-23
BR9714004A (pt) 2000-05-02
US7524944B2 (en) 2009-04-28
EP0948614A2 (en) 1999-10-13
WO1998026061A2 (en) 1998-06-18
IL130247A0 (en) 2000-06-01
EP1806360A2 (en) 2007-07-11
EP0948614B1 (en) 2009-01-14
EP1806360A3 (en) 2007-12-12
CA2274498C (en) 2010-06-29
CA2707726C (en) 2013-10-22
WO1998026061A3 (en) 1998-11-19
US20100267129A1 (en) 2010-10-21
US20060183199A1 (en) 2006-08-17
CA2707726A1 (en) 1998-06-18
NZ336092A (en) 2001-09-28
DE69739220D1 (de) 2009-03-05
NO327411B1 (no) 2009-06-22
NO992756L (no) 1999-08-09
IL178306A0 (en) 2007-02-11
AU5795798A (en) 1998-07-03
ATE420956T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
NO992756L (no) Nye ekspresjonsvektorer inneholdende gener for aksessorisk molekyl ligander og deres anvendelse for immunmodulering og behandling av maligniteter og autoimmune sykdommer
PT662137E (pt) Transcricao de genes e radiacao ionizante: metodos e composicoes
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
IL190793A0 (en) A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
DK1240337T3 (da) Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
ATE437232T1 (de) Rekombinanter adenoviren-vektor und verfahren zur verwendung
DE69707985D1 (de) Kodierende sequenzen des menschlichen brca1-gens
DE3587939D1 (de) Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.
ATE432987T1 (de) Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums
BG103149A (en) Npr genes for acquired resistance and their application
ATE481986T1 (de) Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DK1390403T3 (da) Peptider afledt af nervetrådsproteiner og medicinsk anvendelse deraf
DK1368054T3 (da) Anvendelse af neurale trådproteiner til behandling af tumorer
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
EP1100815A4 (en) PROTEASE TYPE II CLEAVABLE PEPTIDE
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
ATE517122T1 (de) Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
DE59911733D1 (de) Verwendung von adenoassoziierten viren zur senkung der radio- oder chemotherapieinduzierten resistenz bei krebspatienten
ATE516364T1 (de) Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5
ATE105335T1 (de) Traegergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.